Completed PHASE3 INTERVENTIONAL 1-arm NCT00666328

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE) (ACCELERATE)

The Evaluation of Patients With Acute Hypertension and Intracerebral Hemorrhage With Intravenous Clevidipine Treatment (ACCELERATE)

Sponsor: The Medicines Company

Conditions Hemorrhage Hypertension

Interventions clevidipine

Updated 7 times since 2017 Last updated: Aug 21, 2014 Started: Jun 30, 2008 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hemorrhage and Hypertension, this trial is completed. The trial is conducted by The Medicines Company and has accumulated 7 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Charleston, United States , Cleveland, United States , Columbus, United States , Detroit, United States , Durham, United States , Erlangen, Germany , Greensboro, United States , Heidelberg, Germany , Honolulu, United States and 7 more locations